Japan to spend $1.2 billion for 1.6 million courses of Merck's COVID-19 pill

Merck & Co Inc. and partner Ridgeback Biotherapeutics said on Wednesday the Japanese government will pay about $1.2 billion for 1.6 million courses of their COVID-19 antiviral pill molnupiravir.

Countries have rushed to sign deals to buy molnupiravir since data last month showed that when given early in the illness the drug could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.

Merck expects to make 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022.

Molnupiravir, the first oral antiviral medication approved for COVID-19.

On Tuesday, the U.S. government said it would buy another $1 billion worth of molnupiravir.

Now your pharmaceutical can procure Antivirals and Covid Vaccines: ALLVAXX!